Two immunotherapy treatments for patients with high risk early-stage and advanced-stage melanoma have received a recommendation for PBS listing from the Pharmaceutical Benefits Advisory Committee (PBAC). The anti-PD-1 drug nivolumab (Opdivo) was recommended for subsidy the treatment of resected Stage III/IV (high risk) metastatic melanoma by the PBAC at its November meeting. The committee also ...
Two melanoma immunotherapy treatments recommended for PBS listing
By Michael Woodhead
23 Jan 2020